GSK Acquires Sierra Oncology for USD 1.9 Billion GlaxoSmithKline has agreed to buy Sierra Oncology and its lead drug assets, momelotinib, for anemia caused by the blood malignancy myelofibrosis. GSK is paying USD 55 per share in cash for Sierra, a 39% premium to the company's closing share price yesterday, valui...
Find MoreUncomplicated Urinary Tract Infections are one of the most commonly diagnosed infections in the US, with the maximum prevalence in women who are sexually active. A wide range of pathogens can be a reason behind the manifestation of the condition; however, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, ...
Find MoreAelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement. Aelis, clinical-stage French biotech zeroed in on brain disorders...
Find MoreNIH awards USD 107 Million for radical COVID-19 testing tech The National Institutes of Health (NIH) awarded over USD 107 million for radical approaches to testing for COVID-19 and tracing the spread of the disease, including cutting-edge technologies, which could make daily coronavirus testing less interf...
Find MoreNovartis taps Molecular Partners for a novel approach to combat COVID-19 Novartis is spending USD 69 million upfront on a pair of experimental drugs from Molecular Partners. The pact is for MP0420 and MP0423, two antivirals out of the biotech’s so-called DARPin tech, which Molecular Partners says that it has ...
Find MoreGSK eyes robust immune response from RSV vaccine Cold viruses mostly do not get much attention in terms of R&D. They usually make humans feel miserable for a few days, and later than clear up. However, some cold viruses can hit vulnerable people much harder, which leads to pneumonia and hospitalizations. Th...
Find MoreRoche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion. Th...
Find MoreAstraZeneca demonstrates positive early results from its trial evaluating COVID-19 vaccine-AZD1222 In a frenzied race to find a global cure for COVID-19, several pharma players are testing waters and presenting results from clinical studies evaluating their potential candidates. Not long after, Moderna, a U...
Find MoreNovel coronavirus outbreak has created some unprecedented situations in several domains round the World. No vertical is left untouched as the economy tumbles down impacting the human race. Goals of the several industries such as tourism and hospitality that are hit hard, have shifted as they find new ways to create...
Find MoreAstraZeneca aims for summer start for COVID-19 antibody trial AstraZeneca has made its multipronged approach to the development of antibodies against the pandemic SARS-CoV-2 virus. The giant is utilizing its discovery capabilities and assisting in assessing the candidates who were identified in China and the U.S...
Find MoreHear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.